The RCR and SABR Consortium Prostate Workshop - SOLD OUT

Sophie Alexander is a Superintendent Research Radiographer at The Royal Marsden. Sophie’s main activities focus on implementing and optimising novel technology and techniques within the radiotherapy department, primarily focused on MRI guided adaptive radiotherapy on the MR-linac. Sophie also works with the Radiotherapy Trials Quality Assurance group to develop image-guidance protocols in prostate cancer trials, including PACE-NODES.

Prof Cornford was a consultant urological surgeon in Liverpool for 23 years before he fell he needed a new challenge and moved to Cork. He remains honorary Professor at the University of Liverpool. He is also the current chair of the EAU prostate cancer guidelines committee.

Lisa-Jane qualified as a Therapeutic Radiographer 17 years ago and currently works as Deputy Head of Radiotherapy at Royal Surrey NHS Foundation Trust where she oversees the SABR and Adaptive services in addition to managing the day-to-day running of the Radiotherapy Service.

Lisa-Jane was appointed to the UK SABR Consortium Steering Committee in 2021 and since then, has helped to organise and deliver teaching at a number of SABR workshops including Motion Management and Spine.

Chris is a Doctor of Clinical Science and the Lead Physicist for Stereotactic Radiotherapy at Barts Health NHS Trust in London having initially led SABR implementation there in 2011. He was a member of the SABR Consortium QA Sub-group in its infancy and has since contributed to authorship of the SABR Consortium guidance, and specifications for the NHS England Commissioning through Evaluation & SABR Expansion programmes. He is an active member of the committees for the UK SABR Consortium annual conference and also sits on the RCC & Cardiac SABR working parties. Most recently he has recently helped design, and delivered teaching for, the spinal SABR educational workshop run jointly with the Royal College of Radiologists.

Ann Henry is Professor in Clinical Oncology at the University of Leeds and Honorary Consultant Clinical Oncologist at Leeds Teaching Hospitals NHS Trust. She specialises in the radiation treatment of urological cancers. Her research aims to optimise treatments to improve overall survival and reduce treatment related side effects. She is Chief Investigator for POINTER-PC: Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer. POINTER-PC is a Phase III RCT comparing extended nodal irradiation with SBRT for oligo-recurrent pelvic nodal disease. She is a member of the EAU (European Association of Urologists) Prostate Cancer Guidelines group.

Disclosures: Research funding from NIHR, CRUK, Yorkshire Cancer Research

Dr Olly Hulson is a Consultant radiologist at Leeds teaching hospitals with a subspecialty interest in prostate cancer diagnostics and therapeutics. He is involved in delivering the prostate MRI service in Leeds and set up their transperineal prostate biopsy service in 2021. Olly provides radiology support for the prostate brachytherapy service in Leeds and supports the regional prostate oncology MDT. 

Suneil Jain is a Professor of Clinical Oncology at Queens University Belfast and Consultant Clinical Oncologist at the Northern Ireland Cancer Centre. Prof Jain leads multiple clinical trials in Northern Ireland; his research interests include radiomic and genomic biomarkers to improve risk stratification in prostate cancer and stereotactic radiotherapy in high-risk prostate cancer. He is Chief Investigator on the SABRE phase III clinical trial evaluating SpaceOAR Vue in patients treated with stereotactic radiotherapy and Clinical Lead for the PACE NODEs phase III clinical trial. He is Co-Director of the Prostate Cancer Centre of Research Excellence at QUB. 

Olivia Naismith has worked as a Medical Physicist in Radiotherapy since 2003. She joined the National Radiotherapy Trials QA (RTTQA) Group in 2004, based at The Royal Marsden Hospital, as a QA Physicist for prostate trials including CHHiP, PIVOTALboost, PACE, PACE-NODES and STAMPEDE2. Her work has included: helping sites commission IMRT and VMAT treatment planning for prostate RT; contributing to the development of prostate RT treatment procedures and protocols covering the change from conventional fractionation to moderate and extreme hypofractionation; developing a QA programme for adaptive radiotherapy; dosimetry audits; and supporting research using dosimetric data from trial patients.

Dr Angela Pathmanathan is a consultant clinical oncologist at the Royal Marsden Hospital, specialising in the treatment of urological malignancies. She was involved in implementing MRI guided radiotherapy treatment for the first patients treated on the MR-Linac in the UK and completed her research MD thesis in this subject. Dr Pathmanathan has a specialist interest in MR-guided radiotherapy, SBRT and re-irradiation. She is co-clinical lead for the multicentre PACE-NODES trial.

Alison Tree was appointed as a consultant clinical oncologist at the Royal Marsden hospital in 2014, specialising in urological malignancies. She is the GU editor for the International Journal of Radiation Oncology Biology and Physics, the lead journal globally dedicated to radiation-related research.

She is chair of the MR Linac Consortium Steering Committee and teaches on several ESTRO and ASTRO courses. She is Chief Investigator of the TRAP, DELINEATE, HERMES, DESTINATION and PACE C trials and co-investigator of the PIVOTALboost, PACE-NODES, PEARLS and InPACT trials. Her research has received funding from Prostate Cancer UK, Cancer Research UK, the Rosetrees Trust, the JP Moulton foundation, Accuray and Elekta. Her current research interests include technical radiotherapy improvements in localised prostate cancer, oligometastatic and oligoprogressive disease. "

Louise is Lead Research and Development Radiographer at The Clatterbridge Cancer, Merseyside. She has been in this role for 7 years and is particularly interested in SABR, prostate, HPB, motion management, MRI in radiotherapy and Adaptive radiotherapy. 

James has been working as a radiotherapy physicist at the Royal Marsden since 2016, where he focuses on treatment planning and clinical trials. Prior to that he worked at Auckland City Hospital in New Zealand, where he trained as a medical physicist.